60

Shanghai Shyndec Pharmaceutical Co LtdSHG 600420 Stock Report

Last reporting period 30 Sep, 2023

Updated 22 Oct, 2024

Last price

Market cap $B

2.152

Small

Exchange

XSHG - Shanghai Stock Exchange

600420.SS Stock Analysis

60

Neutral

Based on Eyestock quantitative analysis, 600420.SS`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

65/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-21.6 %

Overvalued

Market cap $B

2.152

Dividend yield

1.97 %

Shares outstanding

1 172.09 B

Shanghai Shyndec Pharmaceutical Co., Ltd. principally engages in the research, development, manufacturing, and sale of pharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 11,937 full-time employees. The company went IPO on 2004-06-16. The firm's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The firm also offers topical preparations, such as gynecological suppositories and dermatology preparations.

View Section: Eyestock Rating